Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bone morphogenetic protein 6
- Development stage
- Preclinical
- Lead developer
- Genera Research
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intralesional
01
Overview
Bone morphogenetic protein 6 (BMP6) is a member of the transforming growth factor-beta (TGF-β) superfamily of signaling molecules. It plays a pivotal role in bone metabolism and is the primary endogenous regulator of systemic iron homeostasis through the induction of hepcidin. In the context of bone disease, BMP6 promotes the differentiation of mesenchymal stromal cells (MSCs) into osteoblasts, effectively restoring bone formation that is typically suppressed in conditions like multiple myeloma. Furthermore, BMP6 has demonstrated the ability to directly inhibit the proliferation of certain tumor cells, such as plasma cell malignancies, and attenuate inflammatory phenotypes in the bone marrow microenvironment. As a therapeutic agent, recombinant BMP6 is being investigated for its potential to treat bone loss, iron overload disorders, and specific cancers.
- Brand names
- OSTEOGROW
- Other names
- BMP-6BMP6BMP 6VGR-1VGR1VGR 1Decapentaplegic-related protein 6Vegetal-related protein 1
02
Targets
BMPR1ABMPR1BBMPR2 (Bone morphogenetic protein receptor type II)ACVR1 (Activin receptor type I)
Beyond the preview
Go deeper on bone morphogenetic protein 6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bone morphogenetic protein 6.